{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T06:20:16Z","timestamp":1791958816619,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chromoblastomycosis (CBM) is a chronic subcutaneous mycosis caused by dematiaceous fungi that mainly affects rural workers in tropical and subtropical regions. The disease poses a treatment challenge due to its refractory nature and high relapse rate. To date, few cases have been reported in Peru.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively reviewed epidemiological, clinical, microbiological, and treatment data from CBM cases diagnosed between 2011 and 2024 at the Clinical Mycology Unit of the Instituto de Medicina Tropical Alexander von Humboldt (IMTAvH) in Lima, Peru. Diagnosis was confirmed by the identification of muriform cells either on direct microscopic examination or histopathology.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of the 15 identified cases, 13 had sufficient data for inclusion. In summary, 84% of the patients were men, 77% acquired the disease in the Peruvian Amazon jungle (predominantly in Ucayali and San Martin), the median age was 65.3 years (range: 33\u201385), and the average disease duration was 10.7 years (range: 1\u201325 years). The lower extremities were most frequently affected (53%), followed by the upper extremities (38%). Plaque-like and verrucous lesions were the most common (38% each), whereas tumoral and cicatricial forms were less frequent (15% each). The aetiological agent was identified by morphology in nine patients.\n                      <jats:italic>Fonsecaea sp.<\/jats:italic>\n                      was the most frequently identified pathogen (46%), followed by\n                      <jats:italic>Cladophialophora sp.<\/jats:italic>\n                      (15%) and\n                      <jats:italic>Phialophora sp.<\/jats:italic>\n                      (7%). Nine patients (69%) received oral itraconazole (200\u2013400\u00a0mg\/day) combined with cryosurgery; two (15%) received itraconazole alone; and two (15%) received itraconazole combined with terbinafine (500\u00a0mg\/day). Treatment duration ranged from 5 to 136 months, with six patients (46%) achieving a cure.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>CBM in Peru is likely underdiagnosed and underestimated due to low disease recognition, limited diagnostics in remote areas, and lack of mandatory reporting.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12879-025-11475-4","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T01:46:29Z","timestamp":1756345589000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Chromoblastomycosis in Peru: a retrospective review of 13 cases"],"prefix":"10.1186","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-9914-5441","authenticated-orcid":false,"given":"Mercedes","family":"Sanchez-Diaz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1935-5333","authenticated-orcid":false,"given":"Nicolas Antunez","family":"de Mayolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar","family":"Ramos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5016-8555","authenticated-orcid":false,"given":"Omayra","family":"Chincha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6826-5211","authenticated-orcid":false,"given":"Beatriz","family":"Bustamante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"11475_CR1","unstructured":"Neglected. Accessed on May 7 tropical diseases\u00a02025 [https:\/\/www.who.int\/health-topics\/neglected-tropical-diseases#tab=tab_1]"},{"issue":"8","key":"11475_CR2","doi-asserted-by":"publisher","first-page":"e0009611","DOI":"10.1371\/journal.pntd.0009611","volume":"15","author":"DWCL Santos","year":"2021","unstructured":"Santos DWCL, de Azevedo C, de MPES, Vicente VA, Queiroz-Telles F, Rodrigues AM, de Hoog GS, et al. The global burden of chromoblastomycosis. PLoS Negl Trop Dis. 2021;15(8):e0009611.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"11475_CR3","first-page":"134","volume":"24","author":"S Barroeta","year":"1988","unstructured":"Barroeta S, Mej\u00eda de Alejos A, Franco de Arias C, Prado A, Zamora R. Cromomicosis En El Estado de Lara. Dermatol Venez. 1988;24(2):134\u201337.","journal-title":"Dermatol Venez"},{"key":"11475_CR4","doi-asserted-by":"crossref","unstructured":"Silva JP, de Souza W, Rozental S. Chromoblastomycosis: a retrospective study of 325 cases on Amazonic region (Brazil). Mycopathologia. 1998;143(3):171\u20135.","DOI":"10.1023\/A:1006957415346"},{"key":"11475_CR5","doi-asserted-by":"crossref","unstructured":"Bonifaz A, Carrasco-Gerard E, Sa\u00fal A. Chromoblastomycosis: clinical and mycologic experience of 51 cases. Mycoses. 2001;44(1\u20132):1\u20137.","DOI":"10.1046\/j.1439-0507.2001.00613.x"},{"issue":"2","key":"11475_CR6","first-page":"87","volume":"12","author":"MR Navarrete","year":"2014","unstructured":"Navarrete MR, Arenas R, Estrada VFM, Di\u00e9guez CEA, Mayorga J, Bonifaz A, et al. Chromoblastomycosis in mexico. Review of 603 cases, during seven decades. Dermatol Cosmet Med Quir. 2014;12(2):87\u201393.","journal-title":"Dermatol Cosmet Med Quir"},{"key":"11475_CR7","doi-asserted-by":"crossref","unstructured":"Santos DWCL, Vicente VA, Weiss VA, de Hoog GS, Gomes RR, Batista EMM, et al. Chromoblastomycosis in an endemic area of Brazil: a clinical-epidemiological analysis and a worldwide haplotype network. J Fungi. 2020;6(4): 204.","DOI":"10.3390\/jof6040204"},{"key":"11475_CR8","doi-asserted-by":"publisher","first-page":"e00205","DOI":"10.1590\/0037-8682-0132-2024","volume":"57","author":"LSP Barbosa","year":"2024","unstructured":"Barbosa LSP, Souza YRC, Sasaki CS, Santos DWD, Rossato L. Chromoblastomycosis in brazil: A review of 450 published cases. Rev Soc Bras Med Trop. 2024;57:e00205\u20132024.","journal-title":"Rev Soc Bras Med Trop"},{"key":"11475_CR9","doi-asserted-by":"crossref","unstructured":"Queiroz-Telles F, de Hoog S, Santos DWCL, Salgado CG, Vicente VA, Bonifaz A, et al. Chromoblastomycosis. Clin Microbiol Rev. 2017;30(1):233\u201376.","DOI":"10.1128\/CMR.00032-16"},{"key":"11475_CR10","doi-asserted-by":"crossref","unstructured":"Queiroz-Telles F, Nucci M, Colombo AL, Tob\u00f3n A, Restrepo A. Mycoses of implantation in Latin America: an overview of epidemiology, clinical manifestations, diagnosis and treatment. Med Mycol. 2011;49(3):225\u201336.","DOI":"10.3109\/13693786.2010.539631"},{"key":"11475_CR11","doi-asserted-by":"crossref","unstructured":"Torres-Guerrero E, Isa-Isa R, Isa M, Arenas R. Chromoblastomycosis. Clin Dermatol. 2012;30(4):403\u20138.","DOI":"10.1016\/j.clindermatol.2011.09.011"},{"key":"11475_CR12","doi-asserted-by":"crossref","unstructured":"Restrepo A, Gonzalez A, Gomez I, Arango M, de Bedout C. Treatment of chromoblastomycosis with itraconazole. Ann N Y Acad Sci. 1988;544:504\u201316.","DOI":"10.1111\/j.1749-6632.1988.tb40448.x"},{"issue":"11","key":"11475_CR13","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/j.1365-4362.1992.tb04252.x","volume":"31","author":"F Queiroz-Telles","year":"1992","unstructured":"Queiroz-Telles F, Purim KS, Fillus JN, Bordignon GF, Lameira RP, Van Cutsem J, et al. Itraconazole in the treatment of chromoblastomycosis due to Fonsecaea Pedrosoi. Int J Dermatol. 1992;31(11):805\u201312.","journal-title":"Int J Dermatol"},{"key":"11475_CR14","unstructured":"Cavero J, Delgado V. Cromoblastomicosis Por cladosporium Sp. Folia Dermatol Peru. 2004;15:28\u201331."},{"issue":"3","key":"11475_CR15","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1590\/S1726-46342011000300023","volume":"28","author":"S Sol\u00f3rzano","year":"2011","unstructured":"Sol\u00f3rzano S, Garc\u00eda R, Hern\u00e1ndez-C\u00f3rdova G. Cromomicosis: reporte de Un Caso incapacitante. Rev Peru Med Exp Salud Publica. 2011;28(3):552\u20135.","journal-title":"Rev Peru Med Exp Salud Publica"},{"key":"11475_CR16","doi-asserted-by":"crossref","unstructured":"Ventura-Flores R, Failoc-Rojas V, Silva-D\u00edaz H. Chromoblastomycosis: clinical and microbiological characteristics of a neglected disease. Rev Chilena Infectol. 2017;34(4):404\u20137.","DOI":"10.4067\/s0716-10182017000400404"},{"key":"11475_CR17","doi-asserted-by":"crossref","unstructured":"Carcamo PM, Schwalb A, Seas C. Chromoblastomycosis. A case of a verrucous plaque from the tropics. Am J Trop Med Hyg. 2020;103(2):547\u20138.","DOI":"10.1056\/NEJMicm1913199"},{"key":"11475_CR18","doi-asserted-by":"crossref","unstructured":"Schwalb A, Seas C. Chromoblastomycosis. N Engl J Med. 2020;383(2):e7.","DOI":"10.1056\/NEJMicm1913199"},{"key":"11475_CR19","unstructured":"Galarza-Manyari C. Enfoque de Las micosis profundas En El Per\u00fa. Dermatol Peru. 1996;6(1 suppl):S39-40."},{"key":"11475_CR20","doi-asserted-by":"crossref","unstructured":"Carrion AL. Chromoblastomycosis. Ann N Y Acad Sci. 1950;50(10):1255\u201382.","DOI":"10.1111\/j.1749-6632.1950.tb39826.x"},{"key":"11475_CR21","volume-title":"Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030","author":"World Health Organization","year":"2021","unstructured":"World Health Organization. Ending the neglect to attain the sustainable development goals: a road map for neglected tropical diseases 2021\u20132030. Gen\u00e8ve, Switzerland: World Health Organization; 2021."},{"issue":"10","key":"11475_CR22","doi-asserted-by":"publisher","first-page":"e0012562","DOI":"10.1371\/journal.pntd.0012562","volume":"18","author":"DJ Smith","year":"2024","unstructured":"Smith DJ, Queiroz-Telles F, Rabenja FR, Hay R, Bonifaz A, Grijsen ML, et al. A global chromoblastomycosis strategy and development of the global chromoblastomycosis working group. PLoS Negl Trop Dis. 2024;18(10):e0012562.","journal-title":"PLoS Negl Trop Dis"},{"issue":"2","key":"11475_CR23","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1097\/01.qco.0000216625.28692.67","volume":"19","author":"P Esterre","year":"2006","unstructured":"Esterre P, Queiroz-Telles F. Management of chromoblastomycosis: novel perspectives. Curr Opin Infect Dis. 2006;19(2):148\u201352.","journal-title":"Curr Opin Infect Dis"},{"key":"11475_CR24","doi-asserted-by":"publisher","DOI":"10.3390\/jof10030168","author":"J Valentin","year":"2024","unstructured":"Valentin J, Grotta G, Muller T, Bourgeois P, Drak Alsibai K, Demar M, et al. Chromoblastomycosis in French Guiana: epidemiology and practices, 1955\u20132023. J Fungi. 2024. https:\/\/doi.org\/10.3390\/jof10030168","journal-title":"J Fungi"},{"issue":"8","key":"11475_CR25","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1111\/j.1365-4632.2010.04729.x","volume":"50","author":"MF Mouchalouat","year":"2011","unstructured":"Mouchalouat MF, Gutierrez Galhardo MC, Zancop\u00e9-Oliveira RM, Monteiro Fialho PC, de Oliveira Coelho JMC, Silva Tavares PM, et al. Chromoblastomycosis: a clinical and molecular study of 18 cases in Rio de janeiro, Brazil. Int J Dermatol. 2011;50(8):981\u20136.","journal-title":"Int J Dermatol"},{"key":"11475_CR26","doi-asserted-by":"crossref","unstructured":"Yang CS, Chen CB, Lee YY, Yang CH, Chang YC, Chung WH, et al. Chromoblastomycosis in Taiwan: a report of 30 cases and a review of the literature. Med Mycol. 2018;56(4):395\u2013405.","DOI":"10.1093\/mmy\/myx075"},{"issue":"3","key":"11475_CR27","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/09546630903585074","volume":"22","author":"PR Criado","year":"2011","unstructured":"Criado PR, Careta MF, Valente NYS, Martins JEC, Rivitti EA, Spina R, et al. Extensive long-standing chromomycosis due to Fonsecaea pedrosoi: three cases with relevant improvement under voriconazole therapy. J Dermatol Treat. 2011;22(3):167\u201374.","journal-title":"J Dermatol Treat"},{"key":"11475_CR28","doi-asserted-by":"crossref","unstructured":"Andrade TS, Castro LGM, Nunes RS, Gimenes VMF, Cury AE. Susceptibility of sequential Fonsecaea pedrosoi isolates from chromoblastomycosis patients to antifungal agents. Mycoses. 2004;47(5\u20136):216\u201321.","DOI":"10.1111\/j.1439-0507.2004.00984.x"},{"issue":"Suppl 46","key":"11475_CR29","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1111\/j.1365-2133.1996.tb15658.x","volume":"134","author":"P Esterre","year":"1996","unstructured":"Esterre P, Inzan CK, Ramarcel ER, Andriantsimahavandy A, Ratsioharana M, Pecarrere JL, et al. Treatment of chromomycosis with terbinafine: preliminary results of an open pilot study. Br J Dermatol. 1996;134(Suppl 46):33\u20136.","journal-title":"Br J Dermatol"},{"issue":"Suppl 1","key":"11475_CR30","doi-asserted-by":"publisher","first-page":"S29","DOI":"10.3109\/09546639809160714","volume":"9","author":"P Esterre","year":"1998","unstructured":"Esterre P, Inzan CK, Rtasioharana M, Andriantsimahavandy A, Raharisolo C, Randrianiaina E, et al. A multicenter trial of terbinafine in patients with chromoblastomycosis: effect on clinical and biological criteria. J Dermatol Treat. 1998;9(Suppl 1):S29\u201334.","journal-title":"J Dermatol Treat"},{"key":"11475_CR31","doi-asserted-by":"crossref","unstructured":"Gupta AK, Taborda PR, Sanzovo AD. Alternate week and combination itraconazole and terbinafine therapy for chromoblastomycosis caused by Fonsecaea pedrosoi in Brazil. Med Mycol. 2002;40(5):529\u201334.","DOI":"10.1080\/mmy.40.5.529.534"},{"issue":"5","key":"11475_CR32","doi-asserted-by":"publisher","first-page":"467","DOI":"10.1080\/13693780500543238","volume":"44","author":"M P\u00e9rez-Blanco","year":"2006","unstructured":"P\u00e9rez-Blanco M, Hern\u00e1ndez Valles R, Garc\u00eda-Humbr\u00eda L, Yegres F. Chromoblastomycosis in children and adolescents in the endemic area of the Falc\u00f3n state, Venezuela. Med Mycol. 2006;44(5):467\u201371.","journal-title":"Med Mycol"},{"issue":"4","key":"11475_CR33","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1007\/s11046-011-9434-6","volume":"172","author":"JP Lyon","year":"2011","unstructured":"Lyon JP, Pedroso e Silva Azevedo CM, Moreira LM, de Lima CJ, de Resende MA. Photodynamic antifungal therapy against chromoblastomycosis. Mycopathologia. 2011;172(4):293\u20137.","journal-title":"Mycopathologia"},{"issue":"12","key":"11475_CR34","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1093\/cid\/ciu168","volume":"58","author":"Mda de Sousa","year":"2014","unstructured":"de Sousa Mda, Belda GT, Spina W Jr, Lota R, Valente PR, Brown NS. Topical application of imiquimod as a treatment for chromoblastomycosis. Clin Infect Dis. 2014;58(12):1734\u20137.","journal-title":"Clin Infect Dis"},{"key":"11475_CR35","doi-asserted-by":"crossref","unstructured":"Hu Y, Qi X, Sun H, Lu Y, Hu Y, Chen X, et al. Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro. PLoS Negl Trop Dis. 2019;13(10): e0007849.","DOI":"10.1371\/journal.pntd.0007849"},{"key":"11475_CR36","doi-asserted-by":"crossref","unstructured":"Castro LGM, Pimentel ERA, Lacaz CS. Treatment of chromomycosis by cryosurgery with liquid nitrogen: 15 years\u2019 experience. Int J Dermatol. 2003;42(5):408\u201312.","DOI":"10.1046\/j.1365-4362.2003.01532.x"},{"key":"11475_CR37","doi-asserted-by":"crossref","unstructured":"Kullavanijaya P, Rojanavanich V. Successful treatment of chromoblastomycosis due to Fonsecaea pedrosoi by the combination of itraconazole and cryotherapy. Int J Dermatol. 1995;34(11):804\u20137.","DOI":"10.1111\/j.1365-4362.1995.tb04404.x"},{"key":"11475_CR38","doi-asserted-by":"crossref","unstructured":"Bonifaz A, Mart\u00ednez-Soto E, Carrasco-Gerard E, Peniche J. Treatment of chromoblastomycosis with itraconazole, cryosurgery, and a combination of both. Int J Dermatol. 1997;36(7):542\u20137.","DOI":"10.1046\/j.1365-4362.1997.00085.x"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11475-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-11475-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-11475-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T11:43:00Z","timestamp":1781610180000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12879-025-11475-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["11475"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-11475-4","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"19 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol was approved by the Institutional Review Board (IRB) of Hospital Cayetano Heredia. The IRB waived the requirement for informed consent for clinical data use. Written informed consent was obtained from all participants or from the legal guardians of the deceased patient, whose photos were used in the publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Patients or relatives (in the case of a deceased patient) provided written informed consent for the publication of photos and identifying information.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1075"}}